Ocera Therapeutics fka OCRX

[1millman]

Totally agree with you here sunspotter. If we do some simple math, the cash on hand as of 12/31 was 15.3M. If we add in the 1.6M BMS payment for the 1Q and deduct approximately 1.2 admin expense for the 1Q, that should put us at 15.7M cash at the end of 1Q, assuming that there were no R & D expenses in 1Q. With 27.6M shares O/S, the pps just using cash alone should be .568 which is 29% higher than the .44 close yesterday. BMS has one more installment of 1.6M for the 2Q, so if you add that in the pps cash would be .628. Even if you didn't add any value at all for MATCH, or any future milestones possibilities from BMS, we are still way undervalued IMO. TZYM could be bought by BMS today for .628 and break even on cash alone and get MATCH for free and avoid any future milestones, so the way I see it .628 is a 42.7% gain from where we are today. Barring any unforseen suprises I think we are pretty safe at these levels. I think another possibility would be a merger with BMS or DNDN who may be interested in the technology. John Johnson, C.O.B. of TZYM is the CEO of DNDN. We'll see how it plays out in the future, will definately be interesting.